Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC
K. Lankes, Z. Hassan, M. J. Doffo, C. Schneeweis, S. Lier, R. Oellinger, R. Rad, O. H. Kraemer, U. Keller, D. Saur, M. Reichert, G. Schneider, M. Wirth
The paper identifies bortezomib as a potential therapy for MYC hyperactive pancreatic cancer by showing its sensitivity to proteasome inhibition.
bioRxiv · Jul 1, 2020Cancer Biology